Showing results (181-190 of 824) with videos related to
Sort By:
Pageof 83
Cell Cycle (Georgetown, Tex.)|April 21, 2010
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathwaysKlaus Podar, Kenneth C AndersonSeminars in Hematology|June 26, 2012
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studiesTeru Hideshima, Kenneth C AndersonCancer Letters|February 14, 2006
Caveolin-1 as a potential new therapeutic target in multiple myelomaKlaus Podar, Kenneth C AndersonNature Clinical Practice. Oncology|November 3, 2005
Drug insight: thalidomide as a treatment for multiple myelomaShaji Kumar, Kenneth C AndersonCancers|January 13, 2021
Signaling Pathway Mediating Myeloma Cell Growth and SurvivalTeru Hideshima, Kenneth C AndersonExpert Opinion on Drug Metabolism & Toxicology|July 16, 2008
Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicityIris Breitkreutz, Kenneth C AndersonHematology/Oncology Clinics of North America|November 13, 2007
Preclinical studies of novel targeted therapiesTeru Hideshima, Kenneth C AndersonNature Reviews. Cancer|December 3, 2002
Molecular mechanisms of novel therapeutic approaches for multiple myelomaTeru Hideshima, Kenneth C AndersonCell Cycle (Georgetown, Tex.)|March 14, 2007
Inhibition of VEGF signaling pathways in multiple myeloma and other malignanciesKlaus Podar, Kenneth C AndersonExpert Opinion on Therapeutic Targets|May 26, 2011
CCR1 as a target for multiple myelomaSonia Vallet, Kenneth C AndersonPageof 83